James Edgemond Sells 10,000 Shares of United Therapeutics (NASDAQ:UTHR) Stock

United Therapeutics Corporation (NASDAQ:UTHR) CFO James Edgemond sold 10,000 shares of United Therapeutics stock in a transaction on Thursday, May 28th. The stock was sold at an average price of $565.63, for a total transaction of $5,656,300.00. Following the transaction, the chief financial officer directly owned 18,876 shares of the company’s stock, valued at $10,676,831.88. The trade was a 34.63% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link.

James Edgemond also recently made the following trade(s):

• On Tuesday, May 26th, James Edgemond sold 10,000 shares of United Therapeutics stock. The stock was sold at an average price of $572.94, for a total transaction of $5,729,400.00.
• On Thursday, May 21st, James Edgemond sold 10,000 shares of United Therapeutics stock. The stock was sold at an average price of $564.11, for a total transaction of $5,641,100.00.
• On Monday, May 18th, James Edgemond sold 10,000 shares of United Therapeutics stock. The stock was sold at an average price of $567.31, for a total transaction of $5,673,100.00.
• On Thursday, May 14th, James Edgemond sold 10,000 shares of United Therapeutics stock. The stock was sold at an average price of $574.47, for a total transaction of $5,744,700.00.
• On Monday, May 11th, James Edgemond sold 10,000 shares of United Therapeutics stock. The stock was sold at an average price of $573.03, for a total transaction of $5,730,300.00.
• On Thursday, May 7th, James Edgemond sold 10,000 shares of United Therapeutics stock. The stock was sold at an average price of $578.58, for a total transaction of $5,785,800.00.
• On Monday, May 4th, James Edgemond sold 10,000 shares of United Therapeutics stock. The stock was sold at an average price of $576.93, for a total transaction of $5,769,300.00.
• On Thursday, April 30th, James Edgemond sold 10,000 shares of United Therapeutics stock. The stock was sold at an average price of $572.61, for a total transaction of $5,726,100.00.
• On Monday, April 27th, James Edgemond sold 10,000 shares of United Therapeutics stock. The stock was sold at an average price of $568.83, for a total transaction of $5,688,300.00.
• On Wednesday, April 22nd, James Edgemond sold 364 shares of United Therapeutics stock. The stock was sold at an average price of $575.85, for a total transaction of $209,609.40.

United Therapeutics Stock Down 0.9%

NASDAQ UTHR opened at $556.82 on Friday. The firm has a market capitalization of $23.64 billion, a price-to-earnings ratio of 20.55, a PEG ratio of 1.81 and a beta of 0.60. United Therapeutics Corporation has a 52 week low of $272.12 and a 52 week high of $609.35. The company has a fifty day moving average of $566.51 and a two-hundred day moving average of $515.84.

United Therapeutics (NASDAQ:UTHR) last issued its earnings results on Wednesday, May 6th. The biotechnology company reported $5.82 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $7.00 by ($1.18). The company had revenue of $781.50 million for the quarter, compared to analysts’ expectations of $797.40 million. United Therapeutics had a net margin of 40.62% and a return on equity of 19.24%. The firm’s revenue for the quarter was down 1.6% compared to the same quarter last year. During the same period in the prior year, the firm posted $6.63 earnings per share. Equities research analysts anticipate that United Therapeutics Corporation will post 26.92 EPS for the current year.

Institutional Trading of United Therapeutics

A number of hedge funds have recently added to or reduced their stakes in UTHR. Wellington Management Group LLP lifted its stake in United Therapeutics by 74.5% in the fourth quarter. Wellington Management Group LLP now owns 2,441,492 shares of the biotechnology company’s stock worth $1,189,617,000 after acquiring an additional 1,042,711 shares during the period. Darwin Global Management Ltd. purchased a new stake in United Therapeutics in the third quarter worth about $317,617,000. Norges Bank purchased a new stake in United Therapeutics in the fourth quarter worth about $293,418,000. Avoro Capital Advisors LLC lifted its stake in United Therapeutics by 17.3% in the fourth quarter. Avoro Capital Advisors LLC now owns 2,606,060 shares of the biotechnology company’s stock worth $1,269,803,000 after acquiring an additional 383,838 shares during the period. Finally, Janus Henderson Group PLC lifted its stake in United Therapeutics by 75.1% in the fourth quarter. Janus Henderson Group PLC now owns 796,101 shares of the biotechnology company’s stock worth $387,801,000 after acquiring an additional 341,383 shares during the period. 94.08% of the stock is owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

A number of analysts have recently issued reports on the stock. TD Cowen reissued a “buy” rating on shares of United Therapeutics in a research note on Thursday, May 21st. Wells Fargo & Company raised shares of United Therapeutics from an “equal weight” rating to an “overweight” rating and boosted their target price for the company from $575.00 to $735.00 in a research note on Thursday, May 7th. Jefferies Financial Group reissued a “buy” rating on shares of United Therapeutics in a research note on Monday, March 2nd. Raymond James Financial assumed coverage on shares of United Therapeutics in a research note on Friday, April 10th. They set an “outperform” rating and a $700.00 target price for the company. Finally, UBS Group boosted their target price on shares of United Therapeutics from $655.00 to $705.00 and gave the company a “buy” rating in a research note on Thursday, March 5th. Eleven investment analysts have rated the stock with a Buy rating and two have assigned a Hold rating to the company’s stock. According to data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $619.42.

Key United Therapeutics News

Here are the key news stories impacting United Therapeutics this week:

• Positive Sentiment: United Therapeutics is still drawing support from bullish analyst coverage, including recent higher price targets and buy/overweight ratings, which suggests Wall Street remains constructive on the long-term outlook.
• Positive Sentiment: The company continues to highlight clinical and business-development catalysts, including its PHINDER screening study, xenokidney/EXTEND trial progress, and a planned presentation at the Jefferies Global Healthcare Conference, all of which help keep the growth story visible to investors. Article Title Article Title
• Neutral Sentiment: A separate article referenced United Therapeutics in a broader mid-cap stock discussion, but it did not appear to contain company-specific new information likely to move the stock.
• Negative Sentiment: CEO Martine Rothblatt sold 9,500 shares and CFO James Edgemond sold 10,000 shares this week. Multiple insider sales can weigh on sentiment, especially when they come soon after a disappointing earnings report. Article Title Article Title
• Negative Sentiment: The company’s most recent quarterly results missed estimates on both EPS and revenue, leaving investors with an ongoing fundamental overhang despite strong profitability metrics.

About United Therapeutics

United Therapeutics Corporation (NASDAQ: UTHR) is a biotechnology company dedicated to the development and commercialization of unique products to address life-threatening illnesses. The company’s primary focus has been on pulmonary arterial hypertension (PAH), where it has launched several therapies designed to improve functional capacity and quality of life for patients. Its marketed products include continuous infusion treprostinil (Remodulin), inhaled treprostinil (Tyvaso), oral treprostinil (Orenitram) and tadalafil (Adcirca), each tailored to different modes of administration and patient needs.